| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10156584 | International Journal of Radiation Oncology*Biology*Physics | 2018 | 10 Pages |
Abstract
Adjuvant RNI reduces risk of LRR and DR in patients with breast cancer with axillary metastases who receive NAT across subtypes and particularly decreases the risk of DR in HER2+ breast cancer treated with trastuzumab. Enrollment on the National Surgical Adjuvant Breast and Bowel Project B-51/Radiation Therapy Oncology Group 1304 protocol is encouraged to help determine whether RNI can be omitted in patients with axillary pCR to NAT.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Shane R. MD, PhD, Minjeong PhD, Diane D. MS, Janeiro J. MD, Abigail S. MD, MS, Elizabeth A. MD, PhD, Carlos H. MD, MSc, Sarah MD, Wendy A. MD, PhD, Vicente MD, Aysegul A. MD, Wei T. MD, Simona F. MD, EdM,